Docetaxel Mylan (docetaxel)
Generic
- Region
- 🇪🇺 EU
- Active substance
- docetaxel
- Company
- Mylan S.A.S.
- Status
- Lapsed
- Therapeutic area
- Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms
- EU approval
- Tue 31 Jan 2012
- Designations
- Generic
- Application
- EMEA/H/C/002317
- ATC
- L01CD02
- Official record
- www.ema.europa.eu
Indication
Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Taxotere Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Docetaxel Kabi Authorised · Fresenius Kabi Deutschland GmbH
- 🇪🇺 Docetaxel Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Docetaxel Zentiva (previously Docetaxel Winthrop) Withdrawn · Zentiva k.s.
- 🇪🇺 Docetaxel Teva Withdrawn · Teva B.V.
- 🇪🇺 Taxespira (previously Docetaxel Hospira UK Limited ) Withdrawn · Hospira UK Limited
- 🇪🇺 Docetaxel SUN Application withdrawn · Sun Pharmaceutical Industries Europe B.V.
- 🇪🇺 Docetaxel Teva Pharma Lapsed · Teva Pharma B.V.
- 🇪🇺 Docefrez Withdrawn · Sun Pharmaceutical Industries Europe B.V.
- 🇪🇺 Docetaxel Mylan Application withdrawn · Mylan S.A.S.
Follow Docetaxel Mylan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.